Synchrony Medical has raised $5m to advance the US commercialisation of its LibAirty airway clearance system for alleviating the symptoms of chronic obstructive pulmonary disease (COPD).
Led by Israeli investment firm Edge Medical Ventures, New Jersey-headquartered Synchrony’s oversubscribed funding round also featured participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, and Consensus Business Group (CBG).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
LibAirty is an at-home treatment to manage obstructed mucus in the airways – a key characteristic of COPDs such as emphysema and chronic bronchitis. Comprised of a compression vest used in conjunction with a bilevel positive airway pressure (BiPAP) ventilator, the system applies synchronised compressions to different areas of the chest to clear mucus and prevent infections in the airways from developing.
LibAirty gained US Food and Drug Administration (FDA) clearance in July 2025 and launched on the US market in October 2025. The system’s 510(k) clearance was based on clinical studies conducted at the Medical University of South Carolina (MUSC) and Israel’s Sheba Medical Center. In 20 patients with bronchiectasis, LibAirty was found to be superior as compared with a high-frequency chest wall oscillator (HFCWO) or physiotherapist intervention to assist with airway clearance.
For most people with COPD, short-acting bronchodilator inhalers are the first treatment used. Targeted drugs and other medical devices are also approved for the condition.
Synchrony CEO Anat Shani commented: “This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataShani added that the funding leaves the company “well positioned” to scale its US market presence, expand its clinical evidence base, and advance product innovation.
According to the World health Organization (WHO), COPD is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021. Tobacco smoking accounts for over 70% of COPD cases in high-income countries. Historically, the most common treatments for COPD have included inhaled medicines that open and reduce swelling in the airways, and bronchodilator inhalers to relax the airways and keep them open.
LibAirty was developed through Edge Medical Ventures’ EdgeLabs incubator and is supported by the Israel Innovation Authority (IIA).
Shai Policker, chairman of Synchrony and managing partner at Edge Medical Ventures, commented: “Synchrony exemplifies the type of innovation we seek to support, addressing an unmet clinical need through strong clinical foundations and a clear path to transforming patient care.”
